Agile Therapeutics
AGRX
AGRX was delisted on the 25th of March, 2024.
48 hedge funds and large institutions have $73.6M invested in Agile Therapeutics in 2017 Q1 according to their latest regulatory filings, with 9 funds opening new positions, 13 increasing their positions, 7 reducing their positions, and 18 closing their positions.
86% more repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 7
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
23% less funds holding
Funds holding: 62 → 48 (-14)
45% less capital invested
Capital invested by funds: $133M → $73.6M (-$59.8M)
50% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 18
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
+$1.72M |
| 2 |
RA
Royce & Associates
New York
|
+$1.67M |
| 3 |
BlackRock
New York
|
+$1.6M |
| 4 |
Franklin Resources
San Mateo,
California
|
+$1.59M |
| 5 |
DM
Deerfield Management
New York
|
+$1.44M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
-$9.69M |
| 2 |
PA
Perceptive Advisors
New York
|
-$1.66M |
| 3 |
CC
Caxton Corporation
Princeton,
New Jersey
|
-$1.26M |
| 4 |
HCMT
Highland Capital Management (Texas)
Dallas,
Texas
|
-$813K |
| 5 |
NMC
NEA Management Company
Timonium,
Maryland
|
-$761K |
AGRX Hedge Fund Activity: Q1 2017 in Review
48 of the 4,034 institutional investors tracked by Wall St. Rank reported a position in Agile Therapeutics (AGRX) for Q1 2017, worth a combined $73.6M — down 45% from $133M a quarter earlier.
Sellers outnumbered buyers: 18 funds closed out of AGRX and 9 opened new positions — a net loss of 9 holders — while 7 trimmed existing stakes and 13 added.
The largest buyer was Cormorant Asset Management, adding an estimated $1.72M. The largest seller was Adage Capital Partners, exiting entirely with an estimated $9.69M sold.
- 48 institutional investors held Agile Therapeutics (AGRX) as of Q1 2017, down from 62 in Q4 2016.
- Funds reported $73.6M of Agile Therapeutics stock for Q1 2017, down 45% quarter-over-quarter.
- 9 funds opened new Agile Therapeutics positions in Q1 2017 and 18 closed out, a net change of -9 holders.
- The largest Agile Therapeutics buyer in Q1 2017 was Cormorant Asset Management, an estimated $1.72M added.
- The largest Agile Therapeutics seller in Q1 2017 was Adage Capital Partners, an estimated $9.69M sold.
Based on aggregated 13F filings for Q1 2017.